31 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale
8-K
EX-10.1
ai0rm1
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
5vtzhq in
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
zi02a r8neec
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
s6tg7a d2
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
lomkjz
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
1d7ijuvli erx07h3t
5 Oct 20
Prospectus supplement with pricing info
4:16pm
8-K
EX-10.1
98ubumctla4brj0dzu
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
mtgq1bk96v 1wdaktb
20 Aug 20
Entry into a Material Definitive Agreement
9:30am